vision-research.eu - The Gateway to European Vision Research

Provence Technologies and Neuroptis Biotech partner to develop a new compound for treating dry eye syndrome

June 14, 2012

Provence Technologies, a service provider of specialist fine chemistry and Neuroptis Biotech, specializing in the discovery and development of innovative therapies in neurology and ophthalmology, announce today the further strengthening of their collaboration for transferring the chemical development of Neuroptis Biotech’s drug candidate, ML7, and producing the first GMP batches before the end of 2012.

ML7 is a drug candidate for the treatment of dry eye syndromes. It is the first of a new therapeutic class and has the potential to provide a targeted and effective therapeutic remedy for the millions of people suffering from dry eye syndrome, Gougerot-Sjogren syndrome and inflammations, especially ones caused by allergies.

<- Back to: News